A June 14, 2022, European Pharmaceutical Review (EPR) article about the most recent meeting of EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reports a new drug safety issue involving Xalkori and vision loss found in clinical trials for pediatric patients treated with Xalkori. In relevant part from this EPR article about the EMA’s PRAC … [Read more...]
Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly
Background: Malignant peritoneal mesothelioma (MPM) is a rare disease characterized by atypical symptoms, difficult diagnosis, variable course and poor prognosis, and it develops mainly in elderly individuals. The authors aimed to identify the clinical-pathological characteristics, prognosis, and prognostic factors in elderly [ malignant … [Read more...]
Ukoniq Death Risk is Reason for Ukoniq Drug Recall Says FDA
This June 1, 2022 document, “Drug Safety Communication: FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns”, makes clear it is the Ukoniq death risk that was behind the recent Ukoniq drug recall: Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer … [Read more...]
Five PFAS Chemicals Added to List of Regional Screening and Removal Management Levels by the EPA
Since our January 14, 2022 article about GenX, “EPA to Require Chemical Companies to Test Toxicity of Products“, the Environmental Protection Agency (EPA) has added five per- and polyfluoroalkyl substances (PFAS) to a list of risk-based values that will allow the organization to determine what, if any, remediation activities are needed. The … [Read more...]
J&J, 2-stepping through talc litigation, faces fresh claims it hid workers’ asbestos exposure
Johnson & Johnson’s yearslong talc litigation saga has taken an unexpected turn. U.S. Bankruptcy Judge Michael Kaplan this week denied J&J’s bid to block a lawsuit accusing the company of hiding evidence that its industrial talc operations exposed workers to asbestos, Bloomberg first reported. Decades back, J&J owned the talc mine … [Read more...]
Drug Injury Research: FDA Resources Online Available for Patients
In order to make sure that you are using credible sources if and when you want to do some drug injury research, there is an FDA information site and an FDA database that is searchable which we want you to know are available online. (1) Drug Safety Communications This webpage was developed to provide the public with easy access to important drug … [Read more...]
CDC: Mesothelioma Deaths Up Among Women
While use of asbestos has gone down in the U.S., [ mesothelioma deaths ] still increased 25% among women over the last two decades, researchers found. From 1999 to 2020, mesothelioma deaths among women rose significantly from 489 to 614, though the age-adjusted death rate per 1 million women fell from 4.83 to 4.15, reported Jacek Mazurek, MD, of … [Read more...]
Unexplained Pleural Effusion Leads to the Revelation of a Malignant Mesothelioma: A Case Report
Abstract: Malignant mesothelioma is a rare and aggressive cancer that usually affects subjects with prior asbestos exposure, a major risk factor that has been widely known as carcinogenic, and its use is now controlled if not banned in many areas of the world. Malignant mesothelioma originates from mesothelial surface cells covering the serous … [Read more...]
Pericardial Mesothelioma Presenting as Constrictive Pericarditis
Abstract: This case report presents a 60-year-old gentleman with a significant smoking history and possible asbestos exposure who was referred to the emergency department for atrial fibrillation with a rapid ventricular rate and symptoms of heart failure. Labs showed normal brain natriuretic peptide and troponin I. His echocardiography finding … [Read more...]
Ukoniq Withdrawn From Market Due to Increased Risk of Patient Deaths
The drug company responsible for the lymphoma medicine Ukoniq (umbralisib), TG Therapeutics, indicated in April 2022 that Ukoniq was withdrawn from the market due to an increased risk of death in patients using Ukoniq. This April 15, 2022 Dow Jones piece, “TG Therapeutics Pulls Sole Product Ukoniq Amid Increased Death Risk”, summarizes why … [Read more...]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 21
- Next Page »